Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 3:44 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–19 of 19 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Complex Partial Seizures Clear all

Conditions: Adult Refractory Complex Partial Seizures
Interventions: Sabril; Drug
Lead sponsor: Lundbeck LLC; Industry
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 22
States / cities: San Francisco, California • New Haven, Connecticut • Dover, Delaware + 19 more

Conditions: Drug Resistant Epilepsy, Drop Seizures, Generalized Tonic Clonic Seizure, Complex Partial Seizure, Fall Due to Seizure
Interventions: Hövding inflatable helmet; Device
Lead sponsor: Michael A. Gelfand, MD, PhD; Other
Eligibility: 18 Years to 60 Years
Enrollment: 9 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Epilepsy With Simple or Complex Partial Onset Seizures
Interventions: Eslicarbazepine acetate; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 16 Years to 70 Years
Enrollment: 193 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 103
States / cities: Birmingham, Alabama • Mobile, Alabama • Northport, Alabama + 82 more

Conditions: Drug Resistant Partial Onset Seizure
Interventions: ganaxolone, Placebo; Drug
Lead sponsor: Marinus Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 405 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 33
States / cities: Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 25 more

Conditions: Drug Resistant Partial Onset Seizure
Interventions: ganaxolone; Drug
Lead sponsor: Marinus Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 5
States / cities: Santa Monica, California • Lexington, Kentucky • Golden Valley, Minnesota + 2 more

Conditions: Seizures
Interventions: Retigabine, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 306 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 32
States / cities: Birmingham, Alabama • Huntsville, Alabama • Northport, Alabama + 26 more

Conditions: Epilepsy, Epilepsy, Complex Partial
Interventions: Not listed
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: Not listed
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1994 – 2000
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Epilepsy
Interventions: Ezogabine: USAN Retigabine (International Nonproprietary Name); Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 181 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2017
U.S. locations: 30
States / cities: Birmingham, Alabama • Huntsville, Alabama • Northport, Alabama + 25 more

Conditions: Seizures, Epilepsies, Partial, Epilepsy, Complex Partial, Epilepsy, Generalized, Epilepsy
Interventions: Placebo, Vanquix Auto-Injector (Diazepam Injection); Drug
Lead sponsor: Pfizer; Industry
Eligibility: 2 Years and older
Enrollment: 234 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2014
U.S. locations: 86
States / cities: Northport, Alabama • Little Rock, Arkansas • Irvine, California + 44 more

Conditions: Focal Epilepsy, Generalized Seizure, Drug Refractory Epilepsy
Interventions: UNEEG SubQ device, seizure forecasts, nasal diazepam, Preventative Medication (PM); Device · Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 75 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 3
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota

Conditions: Epilepsy, Complex Partial
Interventions: ganaxolone; Drug
Lead sponsor: Marinus Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 7
States / cities: Los Angeles, California • Lexington, Kentucky • Albany, New York + 3 more

Conditions: Epilepsy
Interventions: Not listed
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: 2 Years and older
Enrollment: 1,278 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2018
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Epilepsy, Complex Partial
Interventions: Zonisamide; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 16 Years and older
Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2004
U.S. locations: 25
States / cities: Birmingham, Alabama • Huntsville, Alabama • Northport, Alabama + 22 more

Conditions: Complex Partial Seizures
Interventions: vigabatrin; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Tuberous Sclerosis Complex-associated Refractory Seizures
Interventions: RAD001, Placebo, Antiepileptic drug (1 to 3 only), open label RAD001 (only used for post-extension phase); Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 2 Years to 65 Years
Enrollment: 366 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 22
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 18 more

Conditions: Epilepsy
Interventions: Not listed
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2008
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Seizures
Interventions: Retigabine, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 539 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 2
States / cities: Bethesda, Maryland • Dallas, Texas

Conditions: Adrenocortical Adenoma, Endometrial Stromal Sarcomas
Interventions: MRI, CT or ultrasound was permitted if MRI was contraindicated, Dexamethasone Supression Test, Sonogram, Biopsy, BGG492; Procedure · Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 4
States / cities: Tallahassee, Florida • Baltimore, Maryland • Hoffman, New Jersey + 1 more

Conditions: Partial Epilepsy, Catamenial Epilepsy
Interventions: Ganaxolone, Placebo; Drug · Other
Lead sponsor: Marinus Pharmaceuticals; Industry
Eligibility: 18 Years to 69 Years
Enrollment: 147 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 27
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 23 more

Search by objective public record fields.

A Study of the Structure and Function of the Retina in Adult Patients With Refractory Complex Partial Seizures Treated With Vigabatrin (Sabril®)

Novel Helmet Design in Patients With Seizures

Safety and Efficacy of Eslicarbazepine Acetate Monotherapy in Subjects With Partial Epilepsy Not Well Controlled by Current Antiepileptic Drugs

Phase 3 Study of Adjunctive Ganaxolone in Adults With Drug-resistant Partial Onset Seizures and Open-label Extension

A Two-year Open-label Extension Study of Ganaxolone in Patients With Drug-resistant Partial-onset Seizures

Retigabine (Adjunctive Therapy) Efficacy and Safety Study for Partial Onset Refractory Seizures in Epilepsy

Effect of Vigabatrin on Brain Blood Flow and Glucose Metabolism

Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial

Efficacy and Safety of Diazepam in the Management of Refractory Epilepsy in Selected Patients Who Require Intermittent Medical Intervention for Acute Repetitive Seizures.

Optimizing Therapy in Epilepsy Using Seizure Forecasts Via EEG and Wearables

A Treatment Use Protocol for Subjects Continuing on From the Open-label Extension 0601

Evaluation and Treatment of Patients With Epilepsy

Dose Response Study of Zonegran in Patients With Newly Diagnosed Epilepsy

Sabril for Complex Partial Seizures in Adult Tolerability Study (TS) Patients

A Placebo-controlled Study of Efficacy & Safety of 2 Trough-ranges of Everolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) & Refractory Partial-onset Seizures

Role of Hormones in Susceptibility to Seizures in Women With Epilepsy

Retigabine Efficacy and Safety Trial for Partial Onset Refractory Seizures in Epilepsy

Medical Safety Follow-up Study for Patients Who Received More Than 28 Days of Total Exposure to BGG492

A Randomized, Controlled Trial of Ganaxolone in Adult Uncontrolled Partial-Onset Seizures